Drug intelligence / Profile preview

Rhea-001

Development stage: Preclinical
Lead developer: Rhea Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

Rhea-001 is a small molecule antifungal agent being developed by Rhea Pharmaceuticals for the treatment of severe systemic fungal infections, including candidiasis and aspergillosis. It demonstrates potent activity against drug-resistant fungal strains, specifically those resistant to fluconazole and voriconazole. Currently in the preclinical stage, Rhea-001 is designed for intravenous (IV) administration to address high unmet medical needs in infectious disease management.

Beyond the preview

Go deeper on Rhea-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rhea-001.

Explore the full profile